**Abstract**

**Objective:** It was previously reported that increasing serum level of glucagon-like peptide-2 (GLP-2) is a risk factor of migraine in human. The headache phase of a migraine attack is thought to originate in vasodilation of meningeal blood vessels followed by activation of the nociceptive trigeminal nerve innervating these vessels. However, it is unclear how GLP-2 acts on this pathway. In the present study, we investigated the effects of GLP-2 on the diameter of meningeal blood vessels, and determined the target cells of GLP-2 in the meningeal tissue.

**Methods:** Meningeal preparations were isolated from male ddY mice (5--6 weeks). GLP-2 (10--100 nM) was perfused, and the meningeal arteriolar diameter was measured using infrared-differential interference contrast microscopy. The nitric oxide synthase (NOS) inhibitor, L-nitro-arginine-methyl-ester (L-NAME), was co-perfused with GLP-2. Mice were fixed by cardiac perfusion of 4% paraformaldehyde, and GLP-2 receptors were detected with immunofluorescence staining in the meningeal tissue.

**Results:** GLP-2 (100 nM) dilated the meningeal blood vessels, which was prevented by the co-treatment with L-NAME. In the immunofluorescence staining, GLP-2 receptor-like immunoreactivites were detected in the macrophage marker Iba-1 positive cells, but not in the meningeal artery and isolectin B4, a marker of nociceptive C-fiber, positive neurons.

**Conclusion:** GLP-2 dilates the meningeal blood vessels via macrophage NOS-independent mechanisms. This supports a crucial role of GLP-2 in the development of migraine.
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